Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.
Valneva at a glance
Commercial vaccines for travelers
€m
Total revenues in 2020
Unique vaccine development programs
Integrated
differentiated clinical and pre-clinical assets
robust commercial portfolio
Focused
on prevention of infectious diseases with significant unmet medical need
~700
employees in six countries